The lupus nephritis management renaissance.

Juan M Mejia-Vilet, Ana Malvar, Arnon Arazi, Brad H Rovin

Journal: Kidney international 2022;101(2):242-255

PMID: 34619230

Full Text on Elsevier Science View on PubMed

Abstract

Over the past year, and for the first time ever, the US Food and Drug Administration approved 2 drugs specifically for the treatment of lupus nephritis (LN). As the lupus community works toward understanding how to best use these new therapies, it is also an ideal time to begin to rethink the overall management strategy of LN. In addition to new drugs, this must include how to use kidney biopsies for management and not just diagnosis, how molecular technologies can be applied to interrogate biopsies and how such data can impact management, and how to incorporate LN biomarkers into management paradigms. Herein, we will review new developments in these areas of LN and put them into perspective for disease management now and in the future.

Address: Department of Nephrology, Instituto Nacional de Ciencas Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.; Department of Nephrology, Hospital Fernandez, Buenos Aires, Argentina.; Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, New York, USA.; Department of Medicine and Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Electronic address: [email protected].

DOI: 10.1016/j.kint.2021.09.012